Oslo, Norway-based biotech Circio (OSE: CRNA) has entered into a partnership with UK-based 4basebio (AIM: 4BB) to develop and test synthetic “circVec” DNA vectors.
The project targets in vivo delivery, whereby gene therapy is introduced into specific cells or tissues within the body to address genetic disorders.
Circio’s proprietary circVec platform has demonstrated up to 70 times prolonged RNA half-life and a 15-fold increase in protein levels compared to standard mRNA-based expression in this context.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze